drugset / Trial / NCT01525212
Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the change from baseline in HCV Ribonucleic acid (RNA) on Day 4 following three days of dosing with BMS-929075 in chronically genotype subtype 1a and 1b HCV infected subjects
Timeline
- Start
- 2012-04
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-929075 | Small molecule | 25 mg | Oral |
| Subject | BMS-929075 | Small molecule | 100 mg | Oral |
| Subject | BMS-929075 | Small molecule | 400 mg | Oral |
| Subject | BMS-929075 | Small molecule | 800 mg | Oral |